优化潜在的纳米乳液,以促进皮肤间的格利梅皮里德的递送,并提高其抗糖尿病活性
Marwa H Abdallah1,2, Amr S Abu Lila1,2, Hanan M El-Nahas2
1Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Hail 81442, Saudi Arabia.
Gels (Basel, Switzerland)
|June 27, 2023
概括
这项研究开发了一种新型的纳米乳液凝,用于通过皮肤递送glimepiride (GM). 这种纳米乳液显著增强了转基因基因.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 纳米技术 纳米技术
背景情况:
- 通过皮肤递送药物提供了口服药物的替代方案,特别是对于生物可用性较低的药物.
- 口服降糖剂格莱梅皮里德 (GM) 可以从改进的输送系统中受益.
- 纳米乳液 (NEs) 是有希望的增强通过皮肤的药物透.
研究的目的:
- 设计和验证一种纳米乳液 (NE) 系统,用于通过皮肤输送胺 (GM).
- 将优化的NE纳入凝基,以增强皮肤应用.
- 为了评估通过皮肤的纳米乳液配方的安全性和有效性.
主要方法:
- 使用薄荷/贝加莫特油和Tween 80/Transcutol P.制备的纳米乳液.
- 描述包括球体大小,泽塔潜力,形态学,体外释放和稳定性研究.
- 优化的NE被制成凝,并对物理性质,ex vivo透,皮肤刺激和体内药理学进行评估.
主要成果:
- 球形NE (大小约80纳米,-11.8mV泽塔电位) 呈现出良好的稳定性.
- 观察到体外药物释放的增强和通过皮肤流量的7倍增加.
- 与对照组相比,纳米乳液无刺激性,相对生物利用率增加了10倍.
结论:
- 基于透皮纳米乳液的glimepiride凝是一种安全有效的替代口服的替代品.
- 这种配方显著提高了用于糖尿病管理的全身生物可用性.
- 纳米分子技术有望改善生物可用性较差的药物的输送.
相关概念视频
Oral Hypoglycemic Agents: Glinides
189
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
189
Factors Affecting Dissolution: Particle Size and Effective Surface Area
898
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
898
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
210
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
210
Glucagon-like Receptor Agonists
366
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
366
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214


